Cambia

Cambia is a brand name of diclofenac, approved by the FDA in the following formulation(s):

CAMBIA (diclofenac potassium - for solution; oral)

• 
  Manufacturer: NAUTILUS NEUROSCIENC
  
  Approval date: June 17, 2009
  
  Strength(s): 50MG ^[RLD]

Has a generic version of Cambia been approved?

No. There is currently no therapeutically equivalent version of Cambia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cambia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical compositions based on Diclofenae
  Patent 6,974,595
  Issued: December 13, 2005
  Inventor(s): Reiner; Alberto & Reiner; Giorgio
  Assignee(s): ProEthic Pharmaceuticals, Inc.
  New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.
  
  Patent expiration dates:
  
  
  • May 15, 2017
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  



• 
  Pharmaceutical compositions and methods of treatment based on diclofenac
  Patent 7,482,377
  Issued: January 27, 2009
  Inventor(s): Reiner; Alberto & Reiner; Giorgio
  Assignee(s): Kowa Pharmaceuticals America, Inc.
  New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.
  
  Patent expiration dates:
  
  
  • May 15, 2017
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Diclofenac formulations and methods of use
  Patent 7,759,394
  Issued: July 20, 2010
  Inventor(s): Reiner; Giorgio & Reiner; Alberto & Meyer; Andreas
  Assignee(s): APR Applied Pharma Research SA
  Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
  
  Patent expiration dates:
  
  
  • June 16, 2026
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Diclofenac formulations and methods of use
  Patent 8,097,651
  Issued: January 17, 2012
  Inventor(s): Reiner; Giorgio & Reiner; Alberto & Meyer; Andreas
  Assignee(s): APR Applied Pharma Research s.a.
  Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
  
  Patent expiration dates:
  
  
  • June 16, 2026
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 17, 2012 - NEW DOSAGE FORM
  
  

See also...

• Cambia Consumer Information (Drugs.com)
• Cambia Powder Packets Consumer Information (Wolters Kluwer)
• Cambia Consumer Information (Cerner Multum)
• Cambia Advanced Consumer Information (Micromedex)
• Diclofenac Consumer Information (Drugs.com)
• Diclofenac Consumer Information (Wolters Kluwer)
• Diclofenac Enteric-Coated Tablets Consumer Information (Wolters Kluwer)
• Diclofenac Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Diclofenac Immediate-Release Tablets Consumer Information (Wolters Kluwer)
• Diclofenac Potassium Powder Packets Consumer Information (Wolters Kluwer)
• Diclofenac Consumer Information (Cerner Multum)
• Diclofenac Advanced Consumer Information (Micromedex)
• Diclofenac Potassium AHFS DI Monographs (ASHP)
• Diclofenac Sodium AHFS DI Monographs (ASHP)
• Diclofenac epolamine AHFS DI Monographs (ASHP)